GENERAL EQUIPMENT FOR MEDICAL IMAGING SA

Their core work

Oncovision is a Valencia-based SME that designs and manufactures dedicated medical imaging devices, with a core focus on brain-dedicated Positron Emission Tomography (PET) scanners. Their flagship product targets early detection of Alzheimer's disease by identifying β-amyloid biomarkers in the brain. Beyond their own device development, they contribute imaging expertise to large-scale European neuroscience research infrastructures, including the Human Brain Project. They sit at the intersection of medical device engineering and computational neuroscience.

What they specialise in

How they've shifted over time

Oncovision's H2020 journey began in 2014 with a clear product focus: developing their brain-dedicated PET scanner through the SME Instrument pathway (Phase 1 feasibility in 2014, Phase 2 full development in 2016). From 2018 onward, their focus expanded significantly into large-scale neuroscience research infrastructure — joining the Human Brain Project ecosystem through ICEI and HBP SGA3, which brought them into contact with high-performance computing, neuroinformatics, brain modeling, and federated data infrastructures. This shift suggests a company that matured from a single-product medical device SME into a recognized contributor within Europe's premier brain research initiative.

Oncovision is moving from standalone medical device development toward integration with large-scale computational neuroscience platforms, positioning themselves where imaging hardware meets brain data infrastructure.

How they like to work

Oncovision operates in two distinct modes: as a project leader for their own product development (coordinating both CAREMiBRAIN phases), and as a specialist contributor within very large research consortia (HBP has hundreds of partners). Their 158 unique partners across 19 countries is largely driven by participation in the massive Human Brain Project consortium rather than by building their own extensive network. This dual profile — independent SME innovator plus embedded contributor in flagship EU initiatives — suggests they are both self-directed and able to integrate into complex multi-partner environments.

Their network spans 158 partners across 19 countries, but this is heavily influenced by the Human Brain Project's massive consortium. Their organic network (from self-coordinated projects) is likely much smaller, centered on medical imaging and neuroscience partners in Western Europe.

What sets them apart

Oncovision occupies a rare niche: they are one of very few European SMEs building organ-dedicated PET scanners specifically for the brain, rather than general-purpose imaging equipment. Their successful progression through both SME Instrument phases demonstrates that the EU's own reviewers validated their commercial potential. Their integration into the Human Brain Project gives them direct access to Europe's top neuroscience research community — a combination of hardware manufacturing capability and research network that few medical device SMEs can match.

Highlights from their portfolio

• CAREMIBRAIN
  Received EUR 4.4M through SME Instrument Phase 2 — one of the larger SME awards — to commercialize a brain-dedicated PET scanner for Alzheimer's early detection.
• HBP SGA3
  Participation in the Human Brain Project's third phase places Oncovision within Europe's flagship neuroscience initiative alongside top research institutions.